In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of heart attack, stroke and death by 23% compared with an older drug. ...

Ozempic® (once-weekly injectable semaglutide) was associated with a 23% reduced risk of heart attack, stroke and death in people with type 2 diabetes and cardiovascular disease on Medicare versus dulaglutide1Data also highlighted Ozempic® was associated with a 26% lower risk of death versus dulaglutide1This study is the first to directly compare these glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications in everyday real-life use. It fills a significant gap in understanding their effects on heart ...

Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.Novo Nordisk said Wednesday that late-stage trial results for its once-daily obesity pill showed "significant" weight reduction and tolerability in line with its blockbuster Wegovy injection, as drugmakers race to get an oral treatment to market.Results from t ...

印第安纳大学医学院儿科学教授、临床糖尿病项目主任Tamara Hannon指出，儿童时期患上的2型糖尿 病，其病情进展比成人患者更为迅猛，且现有治疗手段并非总能达到理想疗效。 Hannon同时也是这项研究的负责人，该研究成果已同步发表于《柳叶刀》杂志。"我非常希望能有这样 一种治疗选择，预计市场需求将十分旺盛，"她表示， 这款药物"有助于改变患有这种复杂疾病的青少 年的长期健康轨迹"。 礼来及其在GLP-1领域的竞争对手诺和诺德(NVO.US)，均已在低至6岁的儿童群体中开展其注射类药物 的临床试验。随着小学生群体中的肥胖和糖尿病发病率大幅攀升，各医疗团体正呼吁采取更积极的干预 措施。目前，诺和诺德的肥胖治疗药物Wegovy和Saxenda已在美国和欧洲获批，适用于12岁及以上人群; 但其糖尿病治疗药物Ozempic尚未获批用于儿童。 礼来的Mounjaro和Zepbound目前仅适用于成人患者。 青少年糖尿病发病率持续上升 这款已被成年糖尿病患者广泛使用的注射类药物，在青少年患者群体中同样显现出益处。在维也纳举行 的欧洲糖尿病研究协会会议上公布的研究结果显示，该药能使青少年患者的血糖水平平均降低约2%， 且 ...

Key Takeaways NVO reported positive data from a sub-analysis of its phase III REDEFINE 1 study on cagrilintide in obesity.Patients on cagrilintide lost 11.8% body weight compared to 2.3% with placebo after 68 weeks.Novo Nordisk plans to launch a dedicated phase III RENEW obesity program for cagrilintide in Q4 2025.Novo Nordisk (NVO) announced positive data from a sub-analysis of its phase III REDEFINE 1 study assessing the efficacy and safety of once-weekly cagrilintide 2.4 mg as a monotherapy, alongside li ...

These dividend payers cranked up their payouts over the past decade, and they could do it again.Are you more interested in overall gains or generating a large stream of passive income? If you're not sure, I've got great news. It doesn't matter. Filling your portfolio with dividend payers is one of the most effective ways to outperform the overall stock market, according to over 50 years of historical data.Between 1973 and 2024, dividend-paying stocks in the benchmark S&P 500 index delivered a 9.2% average a ...

智通财经APP获悉，生产原料药(Active Pharmaceutical Ingredients, 简称APIs)的印度企业正积极筹备计划 供应用于生产诺和诺德(NVO.US)减重药物仿制药关键原料的相关问题。这些减重药物将于明年在多个 主要市场失去专利保护。 从印度本土医药巨头雷迪博士实验室有限公司(Dr Reddy's Laboratories Ltd.)，到麦克劳德制药有限公司 (Macleods Pharmaceuticals Ltd.)等印度供应商均在着手生产原料药，以用于制造司美格鲁肽(semaglutide) 仿制药。诺和诺德公司旗下以司美格鲁肽为主要成分的药物分别以"Wegovy"和"Ozempic"为商品名销 售。而原料药，又称活性药物成分，是生产供患者使用的成品药剂的核心基础原料。 但提前布局或许是成功的关键，尤其是考虑到司美格鲁肽属于结构复杂的生物分子，其仿制难度相对较 大。 野村证券由赛昂·穆克吉(Saion Mukherjee)牵头的分析师团队在7月15日的一份报告中指出，雷迪博士实 验室已投资建设了一座年产550公斤(合1212.5磅)肽类药物的生产设施。总部位于海德拉巴的Gra ...

Topline The Food and Drug Administration sent warning letters to dozens of drug companies— including popular telehealth firm Hims & Hers and pharmaceutical giants Eli Lilly and Novo Nordisk— demanding they correct “false or misleading claims” about some of their popular weight-loss products after President Donald Trump signed an order designed to clamp down on drug advertising.The letters were issued a week ago. (Photo by Sarah Silbiger/Getty Images)Getty ImagesKey FactsThe warning letters were sent to over ...

For the first time, federal health officials are taking aim at telehealth companies promoting unofficial versions of prescription drugs — including popular weight loss medications — as part of the Trump administration’s crackdown on pharmaceutical advertising.The Food and Drug Administration on Tuesday posted more than 100 letters to various drugmakers and online prescribing companies, including Hims & Hers, which has built a multibillion-dollar business centered around lower-cost versions of blockbuster ob ...

Hims & Hers Health Inc. HIMS stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims & Hers Health, dated Sept. 9, addressed to the company’s CEO, Andrew Dudum.HIMS is encountering selling pressure. See the trading setup here.The FDA flagged misleading claims made by Hims & Hers Health regarding its compounded semaglutide products. Semaglutide is an active ingredient in Novo Nordisk A/S’ NVO flagship Wegovy and Ozempic.In a warning letter, the FDA said ...